{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.28","upperLimit":"-0.29","value":"-0.79"},{"groupId":"OG001","lowerLimit":"-1.83","upperLimit":"-0.84","value":"-1.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"The NRS-11 is a self-reported 11-point numerical scale that assesses pain severity. Participants ≥ 8 years of age are asked to select a number from 0 (no pain) to 10 (worst pain you can imagine) that best describes their worst pain. The recall period is 24 hours. The change from baseline is modelled using a mixed-model for repeated measures.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients aged 8 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901) - Self-Report"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901) - Self-Report"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set patients eligible for the instrument at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months","title":"Change From Baseline in Pain as Measured by the Numeric Rating Scale-11 (NRS-11) at Cycle 13.","type":"SECONDARY","unitOfMeasure":"units on a scale"}